title: Malignant metastatic insulinoma-postoperative treatment and follow-up.
abstract: The rarity of malignant insulinoma limits reports on therapeutic strategies and outcome. The treatment and follow-up of 10 patients, all presenting an insulinoma with metastatic disease of the liver and newly diagnosed between 1992 and 2002, is reported. Pancreatic surgery with successful removal of the primary tumor preferentially located in the tail was performed in 7 women and 3 men, median age 55 years (range 36-82 years). If appropriate, 5 patients underwent additional hepatic surgery and lymph node resections. Liver metastases as the major cause of postoperatively persistent hypoglycemia were subsequently treated by repeated transarterial hepatic chemoembolization and chemoperfusion protocols using high-dose transhepatic streptozocin perfusions (3-4 g per session). The current median survival time for all 10 patients is 2.6 years (range: 1.6-9.7 years). Six patients are currently alive with a median survival of 3.7 years (1.7-9.7 years), five of them with stable disease and free of hypoglycemia. Four patients died after a median survival of 1.8 years (range: 1.6-7.5 years) from complications of unmanageable hypoglycemia. It is concluded that the necessity to treat debiliating and life-threatening hypoglycemia in metastatic malignant insulinoma warrants the option of radical endocrine surgery in combination with extended and repeated postoperative chemoembolization of liver metastases.
authors.affiliation: Insulinoma & GEP-Tumor Center, Department of Internal Medicine, Heinrich-Heine-University, Moorenstrasse 5, 40225, Düsseldorf, Germany. starkea@uni-duesseldorf.de
authors.forename: Achim
authors.initials: A
authors.lastname: Starke
authors.forename: Christiane
authors.initials: C
authors.lastname: Saddig
authors.forename: Lothar
authors.initials: L
authors.lastname: Mansfeld
authors.forename: Rainer
authors.initials: R
authors.lastname: Koester
authors.forename: Cyrus
authors.initials: C
authors.lastname: Tschahargane
authors.forename: Peter
authors.initials: P
authors.lastname: Czygan
authors.forename: Peter
authors.initials: P
authors.lastname: Goretzki
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004621:Embolization, Therapeutic; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D007003:Hypoglycemia / Q000209:etiology / Q000517:prevention & control*; D007261:Infusions, Intra-Arterial; D007340:Insulinoma / Q000150:complications / Q000556:secondary* / Q000628:therapy*; D008113:Liver Neoplasms / Q000150:complications / Q000556:secondary* / Q000628:therapy*; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000150:complications / Q000473:pathology* / Q000601:surgery; D012189:Retrospective Studies; D013311:Streptozocin / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000903:Antibiotics, Antineoplastic; D013311:Streptozocin